How the IRAKM–Mincle immune pathway affects alcoholic liver disease
IRAKM and MINCLE in ALD
['FUNDING_R01'] · CLEVELAND CLINIC LERNER COM-CWRU · NIH-11143097
This project tests whether targeting the IRAKM–Mincle immune pathway can lower liver inflammation in people with alcoholic liver disease.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | CLEVELAND CLINIC LERNER COM-CWRU (nih funded) |
| Locations | 1 site (CLEVELAND, UNITED STATES) |
| Trial ID | NIH-11143097 on ClinicalTrials.gov |
What this research studies
If you have alcohol-related liver disease, researchers are looking at a specific immune sensor called Mincle and its partner IRAKM that may link dead liver cells to ongoing inflammation. They will measure a molecule called GluCer in blood from patients and compare those levels with disease severity. In parallel, lab and mouse experiments will test how blocking Mincle or its signaling alters inflammasome activation and liver scarring. The work combines human blood samples with preclinical tests to point toward new immune-focused treatments.
Who could benefit from this research
Good fit: Ideal candidates are people with alcohol-associated hepatitis or other forms of alcoholic liver disease who can provide blood samples or clinical information.
Not a fit: People without alcoholic liver disease or those with end-stage cirrhosis unlikely to recover from advanced scarring may not benefit directly from this research.
Why it matters
Potential benefit: If successful, this work could point to new therapies that reduce liver inflammation and slow progression to fibrosis or cirrhosis in alcoholic liver disease.
How similar studies have performed: Animal and laboratory studies have suggested Mincle and IRAKM play a role in liver inflammation, but translating these findings into human therapies remains largely untested.
Where this research is happening
CLEVELAND, UNITED STATES
- CLEVELAND CLINIC LERNER COM-CWRU — CLEVELAND, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: NAGY, LAURA E. — CLEVELAND CLINIC LERNER COM-CWRU
- Study coordinator: NAGY, LAURA E.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alcoholic Liver Diseases